Table 1.
The correlation of SNHG9 with the clinicopathological characteristics of PTC patients in the FUSCC.
| Clinical parameters | SNHG9 expression | P-value | |
|---|---|---|---|
| High (%) | Low (%) | ||
| Age(years) | 0.325 | ||
| <55 | 13 (55.2) | 19 (41.3) | |
| ≥55 | 11 (44.8) | 27 (58.7) | |
| Gender | 0.534 | ||
| Male | 6 (20.7) | 8 (17.5) | |
| Female | 18 (79.3) | 38 (82.5) | |
| Tumor size (cm) | 0.034* | ||
| ≤1 | 20 (37.9) | 26 (60.3) | |
| >1 | 4 (62.1) | 20 (39.7) | |
| Location of the primary tumors Solitary lesion | 0.579 | ||
| Upper third | 3 (12.5) | 10 (21.7) | |
| Middle third | 13 (54.2) | 20 (43.5) | |
| Lower third | 4 (16.7) | 11 (23.9) | |
| Isthmus | 4 (16.7) | 5 (10.9) | |
| Extrathyroidal extension | 0.406 | ||
| Positive | 2 (8.3) | 6 (13.0) | |
| Negative | 22 (91.7) | 40 (87.0) | |
| Lymph node metastasis | 0.992 | ||
| Positive | 11 (45.8) | 22 (47.8) | |
| Negative | 13 (54.2) | 24 (52.2) | |
*P < 0.05, Chi-squared test P-value.